Phase II/III study to investigate the efficacy of 5-aminolaevulinic acid (ALA)-based photodynamic therapy in the treatment of Bowen's disease, actinic keratoses and study the effect of dose fractionation for superficial basal cell carcinomas

INTERVENTION: Controlled trial without randomisation; Randomised controlled trial, Random allocation to: 1 Standard photodynamic therapy for superficial basal cell carcinoma 2 Dose fractionated photodynamic therapy CONDITION: Bowen's disease ; Cancer ; Carcinoma in situ of skin PRIMARY OUTCOME: Complete remission of skin tumour and future recurrence. SECONDARY OUTCOME: Not provided at time of registration INCLUSION CRITERIA: Recruited from clinical oncology consultants to whom patients are referred at a district general hospital. Also direct from consultant dermatologists/plastic surgeons in Leeds and Airedale.